Moffitt Cancer Center Awarded $2.5 Million Grant To Develop Novel Therapies For B-Cell Lymphomas

July 26, 2010

TAMPA, Fla. – The National Institutes of Health has awarded a $2.5 million grant to Moffitt Cancer Center researcher Eduardo M. Sotomayor, M.D., to develop novel therapies for B-cell lymphomas and particularly for mantle cell lymphoma.

Moffitt, which treats all types of lymphomas, is one of the referral centers for mantle cell lymphoma, an aggressive type of B-cell non-Hodgkin lymphoma, noted Sotomayor, the Susan and John Sykes Endowed Chair in Hematologic Malignancies.

The NIH R01 grant will be awarded over five years, he said. “These are highly competitive grants, and we are grateful that our peers in the scientific community consider that our work is highly significant and will impact the treatment of patients with B-cell lymphomas.”

Moffitt has a collaboration with investigators at the University of Illinois that will help Moffitt’s investigators to test new drugs for B-cell lymphomas, Sotomayor said.

Moffitt’s Lymphoma Program Team is comprised of basic scientists, clinical investigators and hematopathologists. The program emphasizes translational studies in which scientific discoveries are translated into phase I and II clinical studies, with the aim of finding lifesaving treatments.

About Moffitt Cancer Center

Located in Tampa, Florida, Moffitt Cancer Center is an NCI Comprehensive Cancer Center – a designation that recognizes Moffitt’s excellence in research and contributions to clinical trials, prevention and cancer control. Moffitt currently has 14 affiliates in Florida, one in Georgia and two in Puerto Rico. Additionally, Moffitt is a member of the National Comprehensive Cancer Network, a prestigious alliance of the country’s leading cancer centers, and is listed in U.S. News & World Report as one of “America’s Best Hospitals” for cancer. Moffitt’s sole mission is to contribute to the prevention and cure of cancer.